Healthcare Providers and Services
Company Overview of Personal Genome Diagnostics, Inc.
Personal Genome Diagnostics, Inc. engages in the patient-specific analyses of cancer genome using digital characterization and monitoring technologies. The company provides METDetect Assay for the detection of MET gene amplifications in the circulation of cancer patients with reports that include identification and schematic representation of tumor-specific MET amplifications, annotation of predicted mutation consequences, data summary statistics, and integrated analysis reporting. It also offers LungSelect, a product that identifies common clinically actionable genetic alterations in the plasma of non-small cell lung cancer patients. Personal Genome Diagnostics, Inc. was founded in 2010 and...
855 North Wolfe Street
Baltimore, MD 21205
Founded in 2010
Key Executives for Personal Genome Diagnostics, Inc.
Co-Founder and Chief Medical Officer
Co-Founder and Chief Scientific Officer
Compensation as of Fiscal Year 2015.
Personal Genome Diagnostics, Inc. Key Developments
Personal Genome Diagnostics, Inc. Launches LungSelect™ Product
Jun 11 15
Personal Genome Diagnostics, Inc. announced the launch of its LungSelect™ product that identifies the most common, clinically actionable genetic alterations in the plasma of non-small cell lung cancer (NSCLC) patients. Theresa Zhang, PhD, PGDx's Vice President of Research Services, will present data on LungSelect at the upcoming GTCBio Companion Diagnostics Conference in San Diego. In response to the increasing availability of targeted therapies for NSCLC, clinical guidelines recommend molecular testing of relevant genes to identify candidates for targeted therapy. However, an estimated one-third of NSCLC patients lack adequate tissue samples for molecular testing and therefore cannot be considered for the new targeted treatments. The plasma-based LungSelect test enables testing of all NSCLC patients for relevant sequence mutations, insertions and deletions, and genomic rearrangements, including those patients who may have acquired new mutations post-treatment and those with multiple tumor sites. LungSelect simultaneously identifies somatic sequence mutations and translocations that can be treated with agents already approved by the FDA or that are in clinical trials, including most defined in the NCCN Guidelines®. LungSelect is able to detect sequence mutations and translocations down to 0.02% and 0.1% circulating tumor DNA levels respectively, with sensitivity greater than 90% and positive predictive value greater than 99%. The majority of NSCLC patients with advanced disease have mutations detectable at these circulating tumor DNA levels.
Personal Genome Diagnostics, Inc. Announces Launch of ImmunoSelect Service for Identification of Immunogenic Cancer Mutations
May 29 15
Personal Genome Diagnostics, Inc. announced the launch of its ImmunoSelect service designed to identify mutant neoantigens and support development of immuno-oncology cancer therapies. The new service combines the accuracy of PGDx's CancerXom analysis with its proprietary bioinformatics neoantigen prediction pipeline specifically designed for immuno-oncology applications. Neoantigens are peptides containing tumor-specific mutations that may be capable of inducing an immune response to cancer. The exquisite tumor specificity of neoantigens makes them good targets for immunotherapy. However, identification of the most immunogenic peptides requires highly accurate and comprehensive exome sequencing and tumor-specific mutation detection, as well as use of downstream approaches that filter and validate the results to identify the most promising immunotherapy candidates. PGDx's proven accuracy in exome sequencing and its associated analytic technologies for variant detection have already contributed to advances in clinical immuno-oncology. ImmunoSelect-R is intended to make these approaches more widely available to drug researchers and developers.
Personal Genome Diagnostics, Inc. and Human Longevity, Inc. Sign Cancer Genomics Agreement
Jan 12 15
Personal Genome Diagnostics, Inc. and Human Longevity, Inc. announced that HLI will have access to PGDx's cancer genomics solutions to expand its analysis of cancer genomes, including CancerSelect, PlasmaSelect, CancerXome, METDetect and CancerComplete. HLI has also licensed the PGDx Enterprise Solution platform, which is a turnkey solution that enables laboratories to conduct their own advanced cancer genomic testing using next-generation sequencing. PGDx applies its advanced genomic methods to identify and characterize the unique genomic alterations in tumors using tissue and liquid biopsies from cancer patients. The ES platform utilizes PGDx's proprietary bioinformatics software pipeline that provides sensitivity and specificity, while maximizing accuracy in detecting multiple types of tumor-specific mutations. PGDx's targeted gene panels focus on well-characterized genes that have been selected for their high biologic importance in cancer and their relevance to drug targets and pathways.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 20, 2015